Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13274936 | 0.97 | TLR7 (0.67) | TLR7IL6 | |
| SCHEMBL13275556 | 0.94 | TLR7 (0.61) | TLR7IL6 | |
| SCHEMBL13274388 | 0.91 | TLR7 (0.60) | TLR7IL6 | |
| SCHEMBL12800829 | 0.91 | TLR7 (0.76) | TLR7IL6 | |
| SCHEMBL13274361 | 0.90 | TLR7 (0.66) | TLR7IL6 | |
| SCHEMBL29475674 | 0.87 | TLR7 (0.79) | TLR7IL6 | |
| SCHEMBL1146575 | 0.87 | TLR7 (0.79) | TLR7IL6 | |
| SCHEMBL13275720 | 0.86 | TLR7 (0.61) | TLR7IL6 | |
| SCHEMBL12800359 | 0.85 | TLR7 (0.70) | TLR7IL6 | |
| SCHEMBL15177549 | 0.85 | TLR7 (0.70) | TLR7IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4140485-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| US-11116774-B2 | Modulators of toll-like receptors for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11110091-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20190321366-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10172860-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180085370-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| EP-3210982-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | Gilead Sciences, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170065592-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. | 2017-03-09 | — | — | US | disclosed |
| EP-2818469-B1 | Intermediates for the preparation of modulators of toll-like receptors | GILEAD SCIENCES INC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-9452166-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20140316132-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. | 2014-10-23 | — | — | US | disclosed |
| US-8809527-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140081022-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. | 2014-03-20 | — | — | US | disclosed |
| EP-2364314-B1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES INC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8629142-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130071354-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8367670-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| WO-2010077613-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085370-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | TLR7 9/4885IL6 582/4885 |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | TLR7 9/4885IL6 582/4885 |
| US-11116774-B2 | Modulators of toll-like receptors for the treatment of HIV | TLR7, TLR3, TLR6 | TLR7 1/4885IL6 145/4885 |
| US-20140316132-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | TLR7 9/4885IL6 582/4885 |
| US-10172860-B2 | Modulators of toll-like receptors | TLR3, TLR2, TLR6 | TLR7 9/4885IL6 582/4885 |
| US-11110091-B2 | Modulators of toll-like receptors | TLR3, TLR2, TLR6 | TLR7 9/4885IL6 582/4885 |
| US-20140081022-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | TLR7 9/4885IL6 582/4885 |
| US-20190321366-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | TLR7 9/4885IL6 582/4885 |
| US-20170065592-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | TLR7 9/4885IL6 582/4885 |
| US-20130071354-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | TLR7 9/4885IL6 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.